Hyderabad-based Bharat Biotech has partnered with the University of Wisconsin Madison and US-based company FluGen to develop a vaccine, Coro-Flu, against Covid-19.
CoroFlu will build on the backbone of FluGen’s flu vaccine candidate known as M2SR. M2SR is a self-limiting version of the influenza virus that induces an immune response against the flu.
Kawaoka’s lab will insert gene sequences from SARS-CoV-2, the novel coronavirus that causes the disease Covid-19, into M2SR so that the new vaccine will also induce immunity against the coronavirus.
CoroFlu could be in human clinical trials by the fall of 2020.
Source : Economic Times